Phathom Pharmaceuticals, Inc. Operating Cash Flow

Operating Cash Flow of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending September 29, 2021 was $-29.1 Million (a 2.47% increase compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow increased by 3.07%
  • Annual Operating Cash Flow for 2020 was $-69.7 Million (a 90.87% increase from previous year)
  • Annual Operating Cash Flow for 2019 was $-36.5 Million (a 3468.91% increase from previous year)
  • Twelve month Operating Cash Flow ending September 29, 2021 was $-135 Million (a 6.56% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 94.29% year-over-year
Trailing Operating Cash Flow for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-135 Million $-127 Million $-108 Million $-69.7 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of Phathom Pharmaceuticals, Inc.

Most recent Operating Cash Flowof PHAT including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-29.07 $-28.36 $-49.77
2020 $-28.2 $-20.73 $-9.34 $-11.42 $-69.69
2019 $-23.38 $-7.11 $-5.21 $-0.81 $-36.51
2018 $-0.3 $-0.72 $-1.02

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.